Biotech Values

[FACT-MASTER]

Dew,

Thanks for the follow-up on this story. Imo, this was an extraordinary monetary gain for Nimbus Therapeutics given the clinical stage TAK-279 was at. Obviously Takeda saw a high value proposition in acquiring somewhat early.

Black Diamond Therapeutics is also involved in kinase inhibitors, however deals such as the one Nimbus acquired, imo don't come along every day.

My apologizes for the delay response, i am presently involved in a lengthy legal case, and have zoned out of following my investment interests. Twisted estate case (so not serious in nature, vs. a criminal case).